Ryan Halsted

Ryan Halsted asked if Doximity is observing any changes in the cadence of pharma budgetary decisions, specifically whether the traditional seasonality of upfront and upsell seasons remains the norm or if there's a shift towards a more periodic review and decision-making process. He also inquired about the demand for multi-module integrated offerings.

Answer

Jeff Tangney, CEO and Co-Founder, characterized the late-year budget uncertainty as an 'anomaly,' not a new norm, emphasizing that buying at scale before December 31st typically offers the best economics. He referenced a similar Q4 dynamic two years prior where revenue growth normalized in Q1. Regarding multi-module integrated offerings, Jeff stated that DocDynamic accounted for approximately 45% of bookings this quarter, a significant increase from 18% a year ago, indicating continued strong interest despite its higher minimum cost.

Ryan Halsted followed up by asking about the demand for Doximity's multi-module integrated offerings, specifically DocDynamic.

Answer

Jeff Tangney, Co-founder and CEO, stated that DocDynamic accounted for about 45% of bookings this quarter, a significant increase from 18% a year ago. He noted that it remains an interesting product for many customers, despite its high minimum cost.